Three independent discounted-cash-flow-style models value Emergent Biosolutions, Inc. every trading day. 0 of 3 currently price EBS above its market price.
| Free Cash Flow model | $-148.51 |
| Excess Profit model | $-113.09 |
| Residual Earnings model | $-0.60 |
| Dividend Discount model | — |
| Piotroski F-Score | 6 / 9 |
| Return on invested capital | +7.1% |
| Net debt / EBITDA | 3.8× |
| Gross margin | +56.1% |
| Revenue CAGR | -12.8% |
| Cash conversion | 3.2× |
| Dividend yield | — |
| Buyback yield | -0.9% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open EBS in StockKitty